Approvals· August 23, 2026 · 18 min read
Besremi's August 30 ET PDUFA: Second-Line vs Anagrelide, Not Hydroxyurea
By Ran Chen#PDUFA Date#FDA Approval#Orange Book
Topic
Specialty Drugs
High-cost specialty medications, payer coverage, access barriers, utilization management, and manufacturer support programs.
Specialty· August 9, 2026 · 20 min read
Aesthetic Procedure Adverse Events by the Numbers (2026)
Deals· July 31, 2026 · 19 min read
argenx's $2.2B Forte Biosciences Deal: FB102 Anti-CD122 & Vyvgart Synergy
By Ran Chen#M&A#Immunology#Clinical Evidence
Pipeline· July 22, 2026 · 17 min read
Radioligand Therapy Clinical Trials by the Numbers (2026)
By Ran Chen#Oncology#Clinical Trials#Specialty Drugs
Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Pricing & Access· July 6, 2026 · 16 min read
Merck Portfolio Dossier: Keytruda QLEX, the Januvia Cliff, and a Post-2028 Pipeline
By Ran Chen#Purple Book#Orange Book#Biosimilars
Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics